- 作者：Marshall J. Orloff ; M.D.a ; morloff@ucsd.edu ; Jon I. Isenberg ; M.D.b ; Henry O. Wheeler ; M.D.b ; Kevin S. Haynes ; M.D.b ; Horacio Jinich-Brook ; M.D.b ; Roderick Rapier ; M.D.b ; Florin Vaida ; Ph.D.c ; Robert J. Hye ; M.D.a ; Susan L. Orloff ; M.D.d
- 关键词：Cirrhosis ; Bleeding esophageal varices ; Emergency portacaval shunt ; Endoscopic sclerotherapy ; Hepatocellular carcinoma (HCC) ; Screening for HCC
- 刊名：The American Journal of Surgery
- 出版年：2012
- 出版时间：February 2012
- 年：2012
- 卷：203
- 期：2
- 页码：182-190
- 全文大小：612 K
Background
Ninety percent of patients with hepatocellular carcinoma (HCC) have cirrhosis. Bleeding esophageal varices (BEV) is a frequent complication of cirrhosis. Detection of HCC in cirrhotic patients with BEV has not been studied.Methods
Two hundred eleven unselected patients with cirrhosis and BEV were randomized to endoscopic sclerotherapy (n = 106) or emergency portacaval shunt (n = 105). Diagnostic workup and treatment were initiated within 8 hours. Ninety-six percent had >10 years of follow-up. HCC screening involved serum ¦Á-fetoprotein (AFP) every 3 months, ultrasonography every 6 months, and selective computed tomography (CT).
Results
HCC occurred in 15 patients, all incurable, a mean of 2.94 years after entry. They died a mean 1.33 years after discovery. Serial AFP and ultrasound examinations were unrevealing over a mean of 2.3 years. The mean model of end-stage liver disease score was 12.7 at entry and 17.4 at HCC diagnosis.
Conclusions
Long-term screening by AFP and ultrasound plus selective CT failed to detect HCC at a curable stage. The detection of HCC in cirrhotic patients with BEV remains a serious, unsolved problem. The use of CT for routine screening warrants consideration despite increased costs.